GB0004297D0 - 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses - Google Patents

2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Info

Publication number
GB0004297D0
GB0004297D0 GBGB0004297.8A GB0004297A GB0004297D0 GB 0004297 D0 GB0004297 D0 GB 0004297D0 GB 0004297 A GB0004297 A GB 0004297A GB 0004297 D0 GB0004297 D0 GB 0004297D0
Authority
GB
United Kingdom
Prior art keywords
sup
oxo
pyrrolidine derivatives
preparing
derivatives process
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0004297.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0004297(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Priority to GBGB0004297.8A priority Critical patent/GB0004297D0/en
Publication of GB0004297D0 publication Critical patent/GB0004297D0/en
Priority to MEP-2009-61A priority patent/ME00595B/me
Priority to EP05012174A priority patent/EP1577296A1/en
Priority to CNA2005100999539A priority patent/CN1740150A/zh
Priority to US10/204,275 priority patent/US6713635B2/en
Priority to PL359388A priority patent/PL212197B1/pl
Priority to DE60107216T priority patent/DE60107216T2/de
Priority to DK04007878.4T priority patent/DK1452524T3/da
Priority to ES04007878T priority patent/ES2334998T3/es
Priority to IL15084201A priority patent/IL150842A0/xx
Priority to AT04007733T priority patent/ATE325093T1/de
Priority to CZ20022849A priority patent/CZ20022849A3/cs
Priority to MYPI20053631A priority patent/MY139420A/en
Priority to PCT/EP2001/001956 priority patent/WO2001064637A1/en
Priority to CNB018054455A priority patent/CN1208319C/zh
Priority to SI200130451T priority patent/SI1265862T1/sl
Priority to MYPI20052965A priority patent/MY140593A/en
Priority to AU73896/01A priority patent/AU778510B2/en
Priority to CA002401048A priority patent/CA2401048C/en
Priority to DK04007733T priority patent/DK1447399T3/da
Priority to RU2002124865/04A priority patent/RU2292336C2/ru
Priority to MYPI20010775A priority patent/MY138966A/en
Priority to AT04007878T priority patent/ATE445597T1/de
Priority to CZ2005-763A priority patent/CZ304702B6/cs
Priority to ES01925354T priority patent/ES2248307T3/es
Priority to KR1020057016175A priority patent/KR100720784B1/ko
Priority to EP04007878A priority patent/EP1452524B1/en
Priority to AT01940256T priority patent/ATE282592T1/de
Priority to RU2002124522A priority patent/RU2291860C3/ru
Priority to PCT/EP2001/001992 priority patent/WO2001062726A2/en
Priority to HU0204526A priority patent/HU229514B1/hu
Priority to EG20010172A priority patent/EG24375A/xx
Priority to MXPA02008206A priority patent/MXPA02008206A/es
Priority to AU2001252144A priority patent/AU2001252144C1/en
Priority to EP01940256A priority patent/EP1263727B1/en
Priority to PT04007733T priority patent/PT1447399E/pt
Priority to BRPI0108664A priority patent/BRPI0108664B8/pt
Priority to EP04030940A priority patent/EP1577295A1/en
Priority to AT04008270T priority patent/ATE488500T1/de
Priority to HK03104935.7A priority patent/HK1052695B/zh
Priority to EP05013657A priority patent/EP1604979A1/en
Priority to CZ2002-2850A priority patent/CZ304420B6/cs
Priority to CNB2005100713086A priority patent/CN1303066C/zh
Priority to BR0108657-0A priority patent/BR0108657A/pt
Priority to KR1020057016174A priority patent/KR100681580B1/ko
Priority to HU0500902A priority patent/HU230270B1/hu
Priority to HU0300196A priority patent/HUP0300196A3/hu
Priority to YUP-632/02A priority patent/RS50455B/sr
Priority to AT01925354T priority patent/ATE304999T1/de
Priority to IL15075701A priority patent/IL150757A0/xx
Priority to PL365159A priority patent/PL210121B1/pl
Priority to AU5214401A priority patent/AU5214401A/xx
Priority to CNB018055079A priority patent/CN1179944C/zh
Priority to PL380061A priority patent/PL213669B1/pl
Priority to YUP-631/02A priority patent/RS50454B/sr
Priority to ES04007733T priority patent/ES2264060T3/es
Priority to DE60143493T priority patent/DE60143493D1/de
Priority to JP2001561734A priority patent/JP4121744B2/ja
Priority to KR1020027010960A priority patent/KR100816185B1/ko
Priority to ROA200201076A priority patent/RO121559B1/ro
Priority to ES04008270T priority patent/ES2355140T3/es
Priority to DK01925354T priority patent/DK1265862T3/da
Priority to CA002401033A priority patent/CA2401033C/en
Priority to CNA2005100999524A priority patent/CN1740151A/zh
Priority to JP2001563480A priority patent/JP4081275B2/ja
Priority to ES01940256T priority patent/ES2231501T3/es
Priority to ROA200201141A priority patent/RO121597B1/ro
Priority to EP04007733A priority patent/EP1447399B9/en
Priority to CO01013823A priority patent/CO5280059A1/es
Priority to EP04008270A priority patent/EP1477478B1/en
Priority to MYPI20010763A priority patent/MY127149A/en
Priority to KR1020027010984A priority patent/KR100759145B1/ko
Priority to CO01013822A priority patent/CO5271667A1/es
Priority to PT04007878T priority patent/PT1452524E/pt
Priority to DE60119397T priority patent/DE60119397T2/de
Priority to NZ520448A priority patent/NZ520448A/en
Priority to MXPA02008056A priority patent/MXPA02008056A/es
Priority to DE60140222T priority patent/DE60140222D1/de
Priority to RU2006125756/04A priority patent/RU2355680C2/ru
Priority to DE60113514T priority patent/DE60113514T2/de
Priority to HK03104916.0A priority patent/HK1052516B/zh
Priority to EP01925354A priority patent/EP1265862B1/en
Priority to TW095112074A priority patent/TW200626544A/zh
Priority to TW095112075A priority patent/TW200626545A/zh
Priority to SA01220027A priority patent/SA01220027B1/ar
Priority to SA01220078A priority patent/SA01220078B1/ar
Priority to US10/204,266 priority patent/US6784197B2/en
Priority to IS6472A priority patent/IS2119B/is
Priority to ZA200205671A priority patent/ZA200205671B/en
Priority to IL150842A priority patent/IL150842A/en
Priority to ZA200205837A priority patent/ZA200205837B/en
Priority to IS6481A priority patent/IS2176B/is
Priority to BG107004A priority patent/BG65923B1/bg
Priority to BG107016A priority patent/BG65783B1/bg
Priority to BG109297A priority patent/BG109297A/en
Priority to NO20023995A priority patent/NO324051B1/no
Priority to NO20023997A priority patent/NO324485B1/no
Priority to CU20020181A priority patent/CU23293B7/es
Priority to CU20020180A priority patent/CU23201A3/es
Priority to US10/609,544 priority patent/US6858740B2/en
Priority to US10/693,917 priority patent/US6911461B2/en
Priority to US10/694,090 priority patent/US6806287B2/en
Priority to US10/824,345 priority patent/US6969770B2/en
Priority to US11/028,039 priority patent/US7217826B2/en
Priority to US11/043,176 priority patent/US7358276B2/en
Priority to US11/043,145 priority patent/US20050171187A1/en
Priority to IL166768A priority patent/IL166768A/en
Priority to AU2005200717A priority patent/AU2005200717B2/en
Priority to AU2005200718A priority patent/AU2005200718B2/en
Priority to IS7919A priority patent/IS7919A/is
Priority to IS7922A priority patent/IS2754B/is
Priority to IS7921A priority patent/IS7921A/is
Priority to IS7920A priority patent/IS7920A/is
Priority to IS7923A priority patent/IS7923A/is
Priority to IS7918A priority patent/IS7918A/is
Priority to JP2005217433A priority patent/JP2006022107A/ja
Priority to NO20053645A priority patent/NO20053645L/no
Priority to JP2005217442A priority patent/JP4938259B2/ja
Priority to NO20053644A priority patent/NO20053644L/no
Priority to IL170181A priority patent/IL170181A/en
Priority to RU2005125569/04A priority patent/RU2005125569A/ru
Priority to RU2005125645/04A priority patent/RU2005125645A/ru
Priority to BG109297A priority patent/BG65803B1/bg
Priority to CY20061101045T priority patent/CY1105517T1/el
Priority to JP2007102379A priority patent/JP4769756B2/ja
Priority to US12/000,512 priority patent/US7692028B2/en
Priority to CY20101100031T priority patent/CY1109718T1/el
Priority to US12/656,808 priority patent/US8034958B2/en
Priority to US13/222,477 priority patent/US8492416B2/en
Priority to NO2016005C priority patent/NO2016005I1/no
Priority to BE2016C012C priority patent/BE2016C012I2/fr
Priority to LU92993C priority patent/LU92993I2/xx
Priority to HUS1600017C priority patent/HUS1600017I1/hu
Priority to LTPA2016013C priority patent/LTC1265862I2/lt
Priority to FR16C1001C priority patent/FR16C1001I2/fr
Priority to NL300815C priority patent/NL300815I2/nl
Priority to CY2016022C priority patent/CY2016022I1/el
Priority to NO2023025C priority patent/NO2023025I1/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
GBGB0004297.8A 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses Ceased GB0004297D0 (en)

Priority Applications (138)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
MEP-2009-61A ME00595B (me) 2000-02-23 2001-02-21 2-okso-1-pirolidinski derivati, postupci za njihovo dobijanje i njihove primene
EP05012174A EP1577296A1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
CNA2005100999539A CN1740150A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
US10/204,275 US6713635B2 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
PL359388A PL212197B1 (pl) 2000-02-23 2001-02-21 Sposób wytwarzania pochodnych 2-okso-1-pirolidyny
DE60107216T DE60107216T2 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
DK04007878.4T DK1452524T3 (da) 2000-02-23 2001-02-21 "2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser"
ES04007878T ES2334998T3 (es) 2000-02-23 2001-02-21 Derivado de 2-oxo-1-pirrolidina y sus usos farmaceuticos.
IL15084201A IL150842A0 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
AT04007733T ATE325093T1 (de) 2000-02-23 2001-02-21 ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß
CZ20022849A CZ20022849A3 (cs) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinové deriváty, způsob jejich výroby a jejich použití
MYPI20053631A MY139420A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
PCT/EP2001/001956 WO2001064637A1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
CNB018054455A CN1208319C (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
SI200130451T SI1265862T1 (sl) 2000-02-23 2001-02-21 Derivati 2-okso-1-pirolidina, postopki za njihovo pripravo in njihova uporaba
MYPI20052965A MY140593A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
AU73896/01A AU778510B2 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
CA002401048A CA2401048C (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
DK04007733T DK1447399T3 (da) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser
RU2002124865/04A RU2292336C2 (ru) 2000-02-23 2001-02-21 Производные 2-оксо-1-пирролидина, способ их получения и применения
MYPI20010775A MY138966A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
AT04007878T ATE445597T1 (de) 2000-02-23 2001-02-21 ß2-OXO-1-PYRROLIDINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNGß
CZ2005-763A CZ304702B6 (cs) 2000-02-23 2001-02-21 (4R) a (4S) diastereoizomery (2S)-2-[2-oxo-4-propylpyrrolidinyl] butanamidu, farmaceutická kompozice s jejich obsahem a jejich použití
ES01925354T ES2248307T3 (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y sus usos.
KR1020057016175A KR100720784B1 (ko) 2000-02-23 2001-02-21 2-옥소-1-피롤리딘 유도체, 이의 제조 방법 및 용도
EP04007878A EP1452524B1 (en) 2000-02-23 2001-02-21 "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses"
AT01940256T ATE282592T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
RU2002124522A RU2291860C3 (ru) 2000-02-23 2001-02-21 Производные 2-оксо-1-пирролидина, способ их получения и применения
PCT/EP2001/001992 WO2001062726A2 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
HU0204526A HU229514B1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EG20010172A EG24375A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
MXPA02008206A MXPA02008206A (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrolidina, proceso para prepararlos y sus usos.
AU2001252144A AU2001252144C1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
EP01940256A EP1263727B1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
PT04007733T PT1447399E (pt) 2000-02-23 2001-02-21 Derivado de 2-oxo-1-pirrolidina e as suas utilizacoes farmaceuticas
BRPI0108664A BRPI0108664B8 (pt) 2000-02-23 2001-02-21 composto, composição farmacêutica e uso de um composto
EP04030940A EP1577295A1 (en) 2000-02-23 2001-02-21 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
AT04008270T ATE488500T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidin-derivate, verfahren zu ihrer herstellung und ihre verwendung.
HK03104935.7A HK1052695B (zh) 2000-02-23 2001-02-21 2-氧代-1-吡咯烷衍生物、其製備方法和用途
EP05013657A EP1604979A1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivative and its pharmaceutical uses
CZ2002-2850A CZ304420B6 (cs) 2000-02-23 2001-02-21 2-Oxo-1-pyrrolidinové deriváty, způsob jejich přípravy a jejich použití
CNB2005100713086A CN1303066C (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
BR0108657-0A BR0108657A (pt) 2000-02-23 2001-02-21 Composto, processo para a preparação e uso do mesmo, e, processo para a preparação da (s)-alfa-etil-2-oxo-1-pirrolidina acetamida ou (r)-alfa-etil-2-oxo-1-pirrolidina acetamida
KR1020057016174A KR100681580B1 (ko) 2000-02-23 2001-02-21 2-옥소-1-피롤리딘 유도체, 이의 제조 방법 및 용도
HU0500902A HU230270B1 (hu) 2000-02-23 2001-02-21 (2S)-2-[2-oxo-4-propilpirrolidinil]-butánamid (4R) és (4S) diasztereoizomerjei és gyógyszerészetileg elfogadható sói és ezek gyógyászati alkalmazása
HU0300196A HUP0300196A3 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
YUP-632/02A RS50455B (sr) 2000-02-23 2001-02-21 Derivati 2-okso-1-pirolidina, postupci za njihovo dobijanje i njihove upotrebe
AT01925354T ATE304999T1 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
IL15075701A IL150757A0 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
PL365159A PL210121B1 (pl) 2000-02-23 2001-02-21 Pochodne 2-okso-1-pirolidyny, środek farmaceutyczny i zastosowanie pochodnych 2-okso-1-pirolidyny
AU5214401A AU5214401A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
CNB018055079A CN1179944C (zh) 2000-02-23 2001-02-21 2-氧代-1-吡咯烷衍生物、其制备方法和用途
PL380061A PL213669B1 (pl) 2000-02-23 2001-02-21 Pochodna 2-okso-1-pirolidyny, srodek farmaceutyczny i zastosowanie pochodnej 2-okso-1-pirolidyny
YUP-631/02A RS50454B (sr) 2000-02-23 2001-02-21 Derivati 2-okso-1-pirolidina, postupak njihovog dobijanja i njihove upotrebe
ES04007733T ES2264060T3 (es) 2000-02-23 2001-02-21 Derivado de 2-oxo-1-pirrolidina y sus usos farmaceuticos.
DE60143493T DE60143493D1 (de) 2000-02-23 2001-02-21 2-Oxo-1-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
JP2001561734A JP4121744B2 (ja) 2000-02-23 2001-02-21 ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用
KR1020027010960A KR100816185B1 (ko) 2000-02-23 2001-02-21 2-옥소-1-피롤리딘 유도체, 이의 제조 방법 및 용도
ROA200201076A RO121559B1 (ro) 2000-02-23 2001-02-21 Derivaţi de 2-oxo-1-pirolidină, procedeu de preparare a acestora şi utilizările lor
ES04008270T ES2355140T3 (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrolidina, procedimiento para prepararlos y sus usos.
DK01925354T DK1265862T3 (da) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse
CA002401033A CA2401033C (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
CNA2005100999524A CN1740151A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
JP2001563480A JP4081275B2 (ja) 2000-02-23 2001-02-21 ２−オキソ−１−ピロリジン誘導体、それらの製造法、およびそれらの使用
ES01940256T ES2231501T3 (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrolidina, procedimiento para prepararlos y sus usos.
ROA200201141A RO121597B1 (ro) 2000-02-23 2001-02-21 Derivati de 2-oxo-1-pirolidina, compozitii farmaceutice si utilizarea lor
EP04007733A EP1447399B9 (en) 2000-02-23 2001-02-21 "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses"
CO01013823A CO5280059A1 (es) 2000-02-23 2001-02-21 Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones
EP04008270A EP1477478B1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses.
MYPI20010763A MY127149A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
KR1020027010984A KR100759145B1 (ko) 2000-02-23 2001-02-21 2-옥소-1-피롤리딘 유도체 및 이것의 제조 방법
CO01013822A CO5271667A1 (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1-pirrilidina, porceso para prepararlos y sus aplicaciones
PT04007878T PT1452524E (pt) 2000-02-23 2001-02-21 Derivado de 2-oxo-1-pirrolidina e suas utilizações farmacêuticas
DE60119397T DE60119397T2 (de) 2000-02-23 2001-02-21 "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
NZ520448A NZ520448A (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
MXPA02008056A MXPA02008056A (es) 2000-02-23 2001-02-21 Derivados de 2-oxo-1 pirrolidina, proceso para prepararlos y sus aplicaciones.
DE60140222T DE60140222D1 (de) 2000-02-23 2001-02-21 "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
RU2006125756/04A RU2355680C2 (ru) 2000-02-23 2001-02-21 Производные 2-оксо-1-пирролидина, способ их получения
DE60113514T DE60113514T2 (de) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
HK03104916.0A HK1052516B (zh) 2000-02-23 2001-02-21 2-氧代-1-吡咯烷衍生物、其制备方法和用途
EP01925354A EP1265862B1 (en) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
TW095112074A TW200626544A (en) 2000-02-23 2001-03-13 (2s)-2-[4-(2, 2-difluorovinyl)-2-oxopyrrolidin-1-yl] butanoic acids and thier uses
TW095112075A TW200626545A (en) 2000-02-23 2001-03-13 (2S)-2-[(4S)-4-(2, 2-difluorovinyl)-2-oxopyrrolidin-1-yl] butanamides and their uses
SA01220027A SA01220027B1 (ar) 2000-02-23 2001-04-01 مشتقات 2-اوكسو-1- بيروليدين2-oxo-1-pyrrolidine، وعمليات لتحضيرها واستخداماتها
SA01220078A SA01220078B1 (ar) 2000-02-23 2001-04-24 مشتقات 2-oxo-1 ,وعملية لتحضيرها واستخداماتها
US10/204,266 US6784197B2 (en) 2000-02-23 2002-02-21 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
IS6472A IS2119B (is) 2000-02-23 2002-07-16 2-oxó-1-pýrrólidín afleiður, aðferð til framleiðslu á þeim og notkun þeirra
ZA200205671A ZA200205671B (en) 2000-02-23 2002-07-16 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses.
IL150842A IL150842A (en) 2000-02-23 2002-07-22 History of 2-oxo-1-pyrrolidine, processes for their preparation and use
ZA200205837A ZA200205837B (en) 2000-02-23 2002-07-22 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses.
IS6481A IS2176B (is) 2000-02-23 2002-07-23 2-oxó-1-pýrrólidín afleiður, aðferðir til framleiðslu á þeim og notkun þeirra
BG107004A BG65923B1 (bg) 2000-02-23 2002-08-14 2-оксо-1-пиролидинови производни, методи за тяхното получаване и приложенията им
BG107016A BG65783B1 (bg) 2000-02-23 2002-08-20 2 -оксо-1-пиролидинови производни, метод за тяхното получаване им и приложението им
BG109297A BG109297A (en) 2000-02-23 2002-08-20 2-oxo-1-pyrrolidine derivatives, a process for their preparation and their use
NO20023995A NO324051B1 (no) 2000-02-23 2002-08-22 2-okso-1-pyrrolidinderivater, fremgangsmate for fremstilling av disse og anvendelse av dem
NO20023997A NO324485B1 (no) 2000-02-23 2002-08-22 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
CU20020181A CU23293B7 (es) 2000-02-23 2002-08-26 Derivados de 2-oxo-1-pirrolidina para prepararlos y sus usos
CU20020180A CU23201A3 (es) 2000-02-23 2002-08-26 Derivados de 2-oxo-1-pirrolidina, procesos para prepararlos y sus usos
US10/609,544 US6858740B2 (en) 2000-02-23 2003-07-01 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
US10/693,917 US6911461B2 (en) 2000-02-23 2003-10-28 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US10/694,090 US6806287B2 (en) 2000-02-23 2003-10-28 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
US10/824,345 US6969770B2 (en) 2000-02-23 2004-04-15 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
US11/028,039 US7217826B2 (en) 2000-02-23 2005-01-04 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
US11/043,176 US7358276B2 (en) 2000-02-23 2005-01-27 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US11/043,145 US20050171187A1 (en) 2000-02-23 2005-01-27 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
IL166768A IL166768A (en) 2000-02-23 2005-02-09 2-oxo-1-pyrrolidine derivatives and a process for their preparation
AU2005200717A AU2005200717B2 (en) 2000-02-23 2005-02-17 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
AU2005200718A AU2005200718B2 (en) 2000-02-23 2005-02-17 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
IS7919A IS7919A (is) 2000-02-23 2005-06-29 2-oxó-1-pýrrólidín afleiður, aðferð til framleiðslu á þeim og notkun þeirra
IS7922A IS2754B (is) 2000-02-23 2005-06-29 @@oxó@@@pýrrólidín@afleiða@og@lyfjafræðileg@notkun@hennar
IS7921A IS7921A (is) 2000-02-23 2005-06-29 2-oxó-1-pýrrólidín afleiða og lyfjafræðileg notkun hennar
IS7920A IS7920A (is) 2000-02-23 2005-06-29 2-oxó-1-pýrrólidín afleiður, aðferð til framleiðslu á þeim og notkun þeirra
IS7923A IS7923A (is) 2000-02-23 2005-06-29 2-oxó-1-pýrrólidín afleiða og lyfjafræðileg notkun hennar
IS7918A IS7918A (is) 2000-02-23 2005-06-29 2-oxó-1-pýrrólidín afleiður, aðferð til framleiðslu á þeim og notkun þeirra
JP2005217433A JP2006022107A (ja) 2000-02-23 2005-07-27 ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用
NO20053645A NO20053645L (no) 2000-02-23 2005-07-27 (4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse
JP2005217442A JP4938259B2 (ja) 2000-02-23 2005-07-27 ２−オキソ−１−ピロリジン誘導体、それらの製造方法及びそれらの使用
NO20053644A NO20053644L (no) 2000-02-23 2005-07-27 (2S)-2-[(4S)-4-(2,2-difluorvinyl)-2-oksopyrrolidinyl ]butanamid og farmasoytisk preparat
IL170181A IL170181A (en) 2000-02-23 2005-08-09 (4r) and (4s)-diastereoisomers of (2s)-2-[oxy-4-propylpyrrolidinyl]butanamide, pharmaceutical compositions comprising them and their use for preparing medicaments
RU2005125569/04A RU2005125569A (ru) 2000-02-23 2005-08-11 Производное 2-оксо-1-пирролидина и его применение
RU2005125645/04A RU2005125645A (ru) 2000-02-23 2005-08-12 Производное 2-оксо-1-пирролидина и его применение
BG109297A BG65803B1 (bg) 2000-02-23 2005-09-16 2-оксо-1-пиролидинови производни, метод за получаването им и тяхното използване
CY20061101045T CY1105517T1 (el) 2000-02-23 2006-07-28 2-oxo-1-pyrrolidine παραγωγο και οι φαρμακευτικες του χρησεις
JP2007102379A JP4769756B2 (ja) 2000-02-23 2007-04-10 ２−オキソ−１−ピロリジン誘導体、それらの製造法、およびそれらの使用
US12/000,512 US7692028B2 (en) 2000-02-23 2007-12-13 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
CY20101100031T CY1109718T1 (el) 2000-02-23 2010-01-11 Παραγωγο 2-οξο-1-πυρρολιδινης και οι φαρμακευτικες του χρησεις
US12/656,808 US8034958B2 (en) 2000-02-23 2010-02-17 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US13/222,477 US8492416B2 (en) 2000-02-23 2011-08-31 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
NO2016005C NO2016005I1 (no) 2000-02-23 2016-03-08 2-okso-1-pyrrolidinderivater, farmasøytisk preparat og deres anvendelse for fremstilling av et medikament
BE2016C012C BE2016C012I2 (https=) 2000-02-23 2016-03-09
LU92993C LU92993I2 (fr) 2000-02-23 2016-03-11 Briviact
HUS1600017C HUS1600017I1 (hu) 2000-02-23 2016-04-13 (2S)-2-[2-oxo-4-propilpirrolidinil]-butánamid (4R) és (4S) diasztereoizomerjei és gyógyszerészetileg elfogadható sói és ezek gyógyászati alkalmazása
LTPA2016013C LTC1265862I2 (lt) 2000-02-23 2016-05-04 2-Okso-1-pirolidino dariniai, jų gamybos būdas ir jų panaudojimas
FR16C1001C FR16C1001I2 (fr) 2000-02-23 2016-05-25 "derive de 2-oxo-1-pyrrolidine et ses applications pharmaceutiques"
NL300815C NL300815I2 (https=) 2000-02-23 2016-05-27
CY2016022C CY2016022I1 (el) 2000-02-23 2016-06-30 Παραγωγο 2-οξο-1-πυρρολιδινης και οι φαρμακευτικες του χρησεις
NO2023025C NO2023025I1 (no) 2000-02-23 2023-06-20 Brivaracetam - forlengelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Publications (1)

Publication Number Publication Date
GB0004297D0 true GB0004297D0 (en) 2000-04-12

Family

ID=9886259

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0004297.8A Ceased GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Country Status (43)

Country Link
US (12) US6713635B2 (https=)
EP (8) EP1265862B1 (https=)
JP (5) JP4121744B2 (https=)
KR (4) KR100816185B1 (https=)
CN (5) CN1208319C (https=)
AT (5) ATE488500T1 (https=)
AU (5) AU5214401A (https=)
BE (1) BE2016C012I2 (https=)
BG (4) BG65923B1 (https=)
BR (2) BRPI0108664B8 (https=)
CA (2) CA2401033C (https=)
CO (2) CO5271667A1 (https=)
CU (2) CU23293B7 (https=)
CY (3) CY1105517T1 (https=)
CZ (3) CZ20022849A3 (https=)
DE (5) DE60143493D1 (https=)
DK (3) DK1265862T3 (https=)
EG (1) EG24375A (https=)
ES (5) ES2248307T3 (https=)
FR (1) FR16C1001I2 (https=)
GB (1) GB0004297D0 (https=)
HK (2) HK1052695B (https=)
HU (4) HU230270B1 (https=)
IL (5) IL150757A0 (https=)
IS (8) IS2119B (https=)
LT (1) LTC1265862I2 (https=)
LU (1) LU92993I2 (https=)
ME (1) ME00595B (https=)
MX (2) MXPA02008056A (https=)
MY (4) MY127149A (https=)
NL (1) NL300815I2 (https=)
NO (6) NO324485B1 (https=)
NZ (1) NZ520448A (https=)
PL (3) PL212197B1 (https=)
PT (2) PT1447399E (https=)
RO (2) RO121559B1 (https=)
RS (2) RS50455B (https=)
RU (5) RU2291860C3 (https=)
SA (2) SA01220027B1 (https=)
SI (1) SI1265862T1 (https=)
TW (2) TW200626545A (https=)
WO (2) WO2001064637A1 (https=)
ZA (2) ZA200205671B (https=)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
JP4334344B2 (ja) * 2001-08-10 2009-09-30 ユセベ ファルマ ソシエテ アノニム オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用
AU2002340971B2 (en) * 2001-10-08 2007-04-26 Ucb Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
CN1604776A (zh) 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
CN1735459A (zh) * 2003-01-13 2006-02-15 Ucb公司 氢化催化剂
CA2515090A1 (en) * 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd Process for producing levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
US20050143445A1 (en) * 2003-03-18 2005-06-30 Parthasaradhi Reddy B. Novel crystalline forms of levetiracetam
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
EP1613590A2 (en) 2003-04-16 2006-01-11 Memory Pharmaceutical Corporation 4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
KR101124098B1 (ko) * 2003-09-24 2012-03-21 유씨비 파마, 에스.에이. 2-옥소-1-피롤리딘 유도체를 제조하는 방법
EA010031B1 (ru) 2003-12-02 2008-06-30 Юсб, С.А. Производные имидазола, способы их получения и применения
WO2005121082A1 (en) * 2004-06-11 2005-12-22 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
MXPA06014228A (es) * 2004-06-21 2007-02-14 Warner Lambert Co Preparacion de pregabalina y compuestos relacionados.
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1802615A1 (en) * 2004-10-20 2007-07-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP2308870A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
WO2007031263A1 (en) * 2005-09-15 2007-03-22 Ucb Pharma, S.A. 4-substituted pyrr0lidin-2-0nes and their use
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
JP2009518335A (ja) * 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム ３−カルボキシ−２−オキソ−１−ピロリジン誘導体及びそれらの使用
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
ES2444009T3 (es) * 2006-06-08 2014-02-21 Ucb Pharma, S.A. Co-cristales de pirrolidinonas
EA019757B1 (ru) * 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
DK2076508T3 (da) * 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008132142A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
JP4644881B2 (ja) 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
DK3260118T3 (da) 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
WO2010054009A1 (en) * 2008-11-07 2010-05-14 Novabay Pharmaceuticals, Inc. Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
CN102215828A (zh) * 2008-11-18 2011-10-12 Ucb医药有限公司 包含2-氧代-1-吡咯烷衍生物的延长释放制剂
AU2009317280B2 (en) * 2008-11-18 2014-03-06 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
EP2393483B1 (en) 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
WO2011015349A2 (en) 2009-08-07 2011-02-10 Ucb Pharma, S.A. Methods for enhancing the cognitive function
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
CA2778194C (en) * 2009-10-23 2016-07-12 Ucb Pharma, S.A. 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
US8957218B2 (en) 2011-04-18 2015-02-17 Ucb Pharma S.A. 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
JP6162125B2 (ja) 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
MX353024B (es) * 2011-12-27 2017-12-18 Bio Pharm Solutions Co Ltd Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
US9163055B2 (en) 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
WO2014087367A2 (en) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
US9920136B2 (en) 2013-02-13 2018-03-20 Ark Diagnostics, Inc. Posaconazole immunoassays
EA034135B9 (ru) 2013-03-13 2020-04-10 Тафтс Юниверсити Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
US20180021307A1 (en) 2015-02-20 2018-01-25 Ucb Biopharma Sprl Combination Treatment
WO2016191435A1 (en) * 2015-05-25 2016-12-01 Peng Wang Processes to produce brivaracetam
CN106279074B (zh) * 2015-05-25 2018-06-26 苏州鹏旭医药科技有限公司 一种化合物及其制备方法和在合成布瓦西坦中的用途
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
ES2893301T3 (es) 2015-11-03 2022-02-08 Ucb Biopharma Sprl Proceso para preparar brivaracetam
WO2017076737A1 (en) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
EP3452447A4 (en) 2016-05-03 2019-12-18 The Regents of The University of California INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3571183B1 (en) 2017-01-20 2024-03-06 The Regents of the University of California 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
WO2018141276A1 (zh) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
CN111868039A (zh) 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
WO2019152536A1 (en) 2018-01-30 2019-08-08 The Regents Of The University Of California Inhibitors of the wnt/beta-catenin pathway
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (en) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Method for nucleating crystals from a solution in a capillary tube
CA3097818A1 (en) 2018-05-08 2019-11-14 UCB Biopharma SRL 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110615744B (zh) 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
EP3813841B1 (en) 2018-06-29 2025-08-13 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
BR112021001499A2 (pt) 2018-07-27 2021-04-27 California Institute Of Technology inibidores de cdk e usos dos mesmos
DK3867223T3 (da) 2018-10-17 2026-03-16 Univ California Prodrugs af alpha-ketoglutarat, alpha-ketobutyrat, alpha-ketoisovalerat og alpha-ketoisohexanoat og anvendelser deraf
EP3699173A1 (en) 2018-10-18 2020-08-26 California Institute of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
KR20210068591A (ko) 2018-10-31 2021-06-09 주식회사 인투셀 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도
SG11202105863PA (en) 2018-12-04 2021-07-29 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
EP3944739A4 (en) 2019-02-25 2023-06-21 The Regents of the University of California METHOD OF FRAGMENTATION OF CARBON-CARBON BONDS
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
EP3947387B1 (en) 2019-03-25 2024-10-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
CN114286675A (zh) 2019-06-04 2022-04-05 海格生物科学有限责任公司 作为食欲肽拮抗剂的咪唑衍生物、组合物以及方法
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
AU2020407122A1 (en) 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
WO2021142132A1 (en) 2020-01-07 2021-07-15 The Trustees Of Princeton University Compositions and methods for treatment of disease by manipulation of serine metabolism
WO2021142221A1 (en) 2020-01-10 2021-07-15 The Regents Of The University Of California Compositions and methods for the treatment of neurodegenerative diseases
US20230174460A1 (en) 2020-04-21 2023-06-08 President And Fellowes Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) * 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
WO2022035805A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
CA3191163A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
US20230271918A1 (en) 2020-08-10 2023-08-31 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
CN116782894A (zh) * 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
EP4232161A1 (en) 2020-10-23 2023-08-30 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
AU2021409394A1 (en) 2020-12-21 2023-07-27 Cornell University Peptide-linked drug delivery system
WO2022150574A1 (en) 2021-01-08 2022-07-14 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US12559456B2 (en) 2021-02-03 2026-02-24 Suzhou Brighthope Pharma Tech Co., Ltd Method for preparing levetiracetam and intermediates thereof
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
CN119604494A (zh) 2022-07-13 2025-03-11 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
US20260076939A1 (en) * 2022-08-31 2026-03-19 Korea University Research And Business Foundation Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor
WO2024163711A1 (en) 2023-02-02 2024-08-08 Osmoses Inc. Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
CN116041240B (zh) 2023-02-17 2024-04-09 扬州奥锐特药业有限公司 布立西坦中间体的不对称催化氢化合成方法
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
US12590059B2 (en) 2023-03-28 2026-03-31 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam
WO2025078883A2 (en) 2023-05-06 2025-04-17 Prepaire Labs Limited Organic compound (oxime) to combat chemical warfare agents
US12528770B2 (en) 2023-06-12 2026-01-20 Suzhou Brighthope Pharmatech Co., Ltd. Process for the production of levetiracetam and intermediates thereof
AU2024344058A1 (en) 2023-09-18 2026-04-02 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025072893A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
WO2025106670A1 (en) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025231452A1 (en) 2024-05-02 2025-11-06 Martinez Montemayor Michelle Ergosterol peroxide derivatives and uses thereof
WO2026030679A1 (en) 2024-08-01 2026-02-05 Osmoses Inc. Hollow fiber polymer membranes for fluid separation
WO2026060616A1 (en) 2024-09-20 2026-03-26 Fulcrum Therapeutics, Inc. Phenothiazine and phenoxazine calmodulin inhibitors and methods of use thereof
US20260090998A1 (en) 2024-10-02 2026-04-02 Battelle Memorial Institute Methods of using polymer nanoparticle compositions for treating a disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD92031A (https=)
DE92031C (https=) *
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
SU731892A3 (ru) 1974-10-15 1980-04-30 Монсанто Компани (Фирма) Способ получени оптических изомеров -замещенных -ациламидопропионовых кислот
EP0089901B1 (en) * 1982-03-24 1987-05-13 Prodes S.A. New 2-oxo-1-pyrrolidineacetic acid esters, their methods of production and therapeutic compositions containing the same
EP0089900B1 (en) * 1982-03-24 1985-12-27 Prodes S.A. New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP0645135A1 (de) * 1993-09-29 1995-03-29 Solco Basel AG Hämodialysat enthaltendes Sonnenschutzmittel
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) * 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
CA2475026A1 (en) 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Also Published As

Publication number Publication date
HU230270B1 (hu) 2015-11-30
AU2005200717A1 (en) 2005-03-17
NO2016005I2 (no) 2016-03-08
DE60113514D1 (de) 2005-10-27
HUS1600017I1 (hu) 2020-02-28
NL300815I2 (https=) 2016-07-27
RO121559B1 (ro) 2007-11-30
AU2005200718A1 (en) 2005-03-17
IS2754B (is) 2011-09-15
HUP0300196A2 (hu) 2003-06-28
CO5271667A1 (es) 2003-04-30
BG109297A (en) 2006-06-30
CN1680314A (zh) 2005-10-12
AU778510B2 (en) 2004-12-09
IL166768A (en) 2010-04-15
KR20020075927A (ko) 2002-10-07
NO20053644L (no) 2002-10-22
NO2023025I1 (no) 2023-06-20
MY140593A (en) 2009-12-31
EP1577295A1 (en) 2005-09-21
HK1052695A1 (en) 2003-09-26
DE60140222D1 (de) 2009-11-26
IS6472A (is) 2002-07-16
CY2016022I2 (el) 2016-10-05
RU2006125756A (ru) 2008-01-27
EP1452524B1 (en) 2009-10-14
PT1452524E (pt) 2010-01-18
ATE445597T1 (de) 2009-10-15
EP1265862B1 (en) 2005-09-21
RS50455B (sr) 2010-03-02
AU2005200718B2 (en) 2007-05-24
CN1740150A (zh) 2006-03-01
CY2016022I1 (el) 2016-10-05
MXPA02008206A (es) 2004-04-05
US20030040631A1 (en) 2003-02-27
IS2119B (is) 2006-06-15
ATE325093T1 (de) 2006-06-15
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
US7217826B2 (en) 2007-05-15
US6784197B2 (en) 2004-08-31
IS6481A (is) 2002-07-23
AU2005200717B2 (en) 2007-05-17
IL150757A0 (en) 2003-02-12
JP4121744B2 (ja) 2008-07-23
NO20023997D0 (no) 2002-08-22
WO2001062726A2 (en) 2001-08-30
MEP6109A (en) 2011-12-20
RU2291860C2 (ru) 2007-01-20
US6806287B2 (en) 2004-10-19
IS7922A (is) 2005-06-29
ME00595B (me) 2011-12-20
NO20023997L (no) 2002-10-22
MY138966A (en) 2009-08-28
RO121597B1 (ro) 2007-12-28
AU7389601A (en) 2001-09-12
NO20023995L (no) 2002-10-21
RU2292336C2 (ru) 2007-01-27
ZA200205671B (en) 2003-11-10
NO324051B1 (no) 2007-08-06
US20120035239A1 (en) 2012-02-09
ES2248307T3 (es) 2006-03-16
US20050171188A1 (en) 2005-08-04
IS7919A (is) 2005-06-29
JP2006022107A (ja) 2006-01-26
JP4938259B2 (ja) 2012-05-23
CZ304420B6 (cs) 2014-04-30
CZ20022850A3 (cs) 2003-02-12
EP1604979A1 (en) 2005-12-14
ZA200205837B (en) 2003-11-04
RS50454B (sr) 2010-03-02
LTPA2016013I1 (lt) 2016-05-25
ATE282592T1 (de) 2004-12-15
AU2001252144B2 (en) 2005-04-28
EP1265862A2 (en) 2002-12-18
NO2016005I1 (no) 2016-03-08
CZ20022849A3 (cs) 2003-02-12
EP1447399B1 (en) 2006-05-03
EP1263727A1 (en) 2002-12-11
WO2001062726A3 (en) 2002-01-17
US20050159475A1 (en) 2005-07-21
SA01220027B1 (ar) 2006-09-19
AU5214401A (en) 2001-09-03
BG107016A (en) 2003-04-30
HU0500902D0 (en) 2005-12-28
BG65803B1 (bg) 2009-12-31
KR100816185B1 (ko) 2008-03-21
HUP0300196A3 (en) 2005-10-28
BG65923B1 (bg) 2010-05-31
JP2007182459A (ja) 2007-07-19
JP2003523996A (ja) 2003-08-12
US8034958B2 (en) 2011-10-11
CN1740151A (zh) 2006-03-01
IL150842A0 (en) 2003-02-12
CN1208319C (zh) 2005-06-29
US6713635B2 (en) 2004-03-30
MY139420A (en) 2009-09-30
US7692028B2 (en) 2010-04-06
CN1303066C (zh) 2007-03-07
CA2401033A1 (en) 2001-08-30
BG65783B1 (bg) 2009-11-30
BR0108657A (pt) 2003-04-29
US6858740B2 (en) 2005-02-22
PL210121B1 (pl) 2011-12-30
RU2005125645A (ru) 2007-02-20
US7358276B2 (en) 2008-04-15
NO20053645L (no) 2002-10-22
DE60113514T2 (de) 2006-05-18
CN1179944C (zh) 2004-12-15
EP1447399A1 (en) 2004-08-18
RU2355680C2 (ru) 2009-05-20
PL212197B1 (pl) 2012-08-31
DE60107216T2 (de) 2005-11-03
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
EP1577296A1 (en) 2005-09-21
DE60119397T2 (de) 2007-04-19
RU2291860C3 (ru) 2017-11-16
BR0108664A (pt) 2003-04-29
CA2401033C (en) 2008-07-29
IS2176B (is) 2006-12-15
EP1477478B1 (en) 2010-11-17
EP1263727B1 (en) 2004-11-17
DE60143493D1 (de) 2010-12-30
US20040192757A1 (en) 2004-09-30
KR100759145B1 (ko) 2007-09-14
US20080097109A1 (en) 2008-04-24
CY1109718T1 (el) 2014-08-13
IL150842A (en) 2008-06-05
PL359388A1 (en) 2004-08-23
WO2001064637A1 (en) 2001-09-07
YU63202A (sh) 2005-09-19
JP2003528828A (ja) 2003-09-30
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
ES2231501T3 (es) 2005-05-16
JP2006022108A (ja) 2006-01-26
EP1452524A1 (en) 2004-09-01
BRPI0108664B8 (pt) 2021-05-25
HK1052516B (zh) 2006-02-10
EP1447399B9 (en) 2006-10-18
IS7921A (is) 2005-06-29
FR16C1001I1 (fr) 2016-07-01
MY127149A (en) 2006-11-30
MXPA02008056A (es) 2004-08-12
DK1265862T3 (da) 2006-01-30
KR20050090090A (ko) 2005-09-12
PL365159A1 (en) 2004-12-27
RU2002124865A (ru) 2004-01-10
DE60107216D1 (de) 2004-12-23
CA2401048A1 (en) 2001-09-07
DE60119397D1 (de) 2006-06-08
EP1477478A3 (en) 2004-11-24
KR100720784B1 (ko) 2007-05-23
DK1447399T3 (da) 2006-08-28
IS7923A (is) 2005-06-29
US6911461B2 (en) 2005-06-28
US8492416B2 (en) 2013-07-23
US20050171187A1 (en) 2005-08-04
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
IS7920A (is) 2005-06-29
KR100681580B1 (ko) 2007-02-09
NO20023995D0 (no) 2002-08-22
ATE304999T1 (de) 2005-10-15
JP4769756B2 (ja) 2011-09-07
CY1105517T1 (el) 2010-07-28
YU63102A (sh) 2005-09-19
ES2334998T3 (es) 2010-03-18
US20030120080A1 (en) 2003-06-26
CZ304702B6 (cs) 2014-09-03
ES2264060T3 (es) 2006-12-16
CA2401048C (en) 2009-01-20
CN1404470A (zh) 2003-03-19
IL170181A (en) 2010-11-30
NO324485B1 (no) 2007-10-29
HUP0204526A2 (hu) 2003-04-28
LTC1265862I2 (lt) 2023-09-11
SA01220078B1 (ar) 2006-10-29
US20100222576A1 (en) 2010-09-02
CN1404469A (zh) 2003-03-19
TW200626544A (en) 2006-08-01
ATE488500T1 (de) 2010-12-15
CO5280059A1 (es) 2003-05-30
CU23293B7 (es) 2008-06-30
IL166768A0 (en) 2006-01-15
KR20020075926A (ko) 2002-10-07
CU23201A3 (es) 2007-04-06
FR16C1001I2 (fr) 2017-02-03
EP1477478A2 (en) 2004-11-17
KR20050091112A (ko) 2005-09-14
LU92993I2 (fr) 2016-05-11
US20040092576A1 (en) 2004-05-13
BE2016C012I2 (https=) 2020-01-30
JP4081275B2 (ja) 2008-04-23
US20040116507A1 (en) 2004-06-17
IS7918A (is) 2005-06-29
BRPI0108664B1 (pt) 2016-07-26
ES2355140T3 (es) 2011-03-23
HUP0204526A3 (en) 2005-03-29
PL213669B1 (pl) 2013-04-30
RU2005125569A (ru) 2007-02-20
DK1452524T3 (da) 2010-03-01
HU229514B1 (en) 2014-01-28
US6969770B2 (en) 2005-11-29
EG24375A (en) 2009-03-19
SI1265862T1 (sl) 2006-02-28

Similar Documents

Publication Publication Date Title
GB0004297D0 (en) 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)